# Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses

> **NCT01922284** · PHASE1 · COMPLETED · sponsor: **Imperial College London** · enrollment: 40 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** DNA
- **BIOLOGICAL:** MVA-C
- **BIOLOGICAL:** CN54rgp140
- **BIOLOGICAL:** GLA-AF

## Key facts

- **NCT ID:** NCT01922284
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-01
- **Final completion:** 2015-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-09-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01922284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01922284, "Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01922284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*